Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Androgens play a critical role in the progression of castration-resistant prostate cancer through androgen receptor (AR)-regulated signaling pathways. Progress has been made in the development of potent agents designed to suppress androgen function by blocking the AR, inhibiting the synthesis of androgens, or targeting downstream AR signaling pathways. This review summarizes the development of novel therapies based on current insights into AR signaling pathways in castration-resistant prostate cancer.

Citation

Wenhui Zhu, David S Zhu, Ravi A Madan, James L Gulley, William D Figg, William L Dahut. Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. American journal of therapeutics. 2010 Mar-Apr;17(2):176-81

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 20019584

View Full Text